About | Free Trial

Last Update


This profile was last updated on . .

Is this you? Claim your profile.

Wrong John Kolman?

Dr. John Kolman L.

Executive Director and Head of Translational Medicine


Direct Phone: (302) ***-****       

QPS Holdings, LLC


1 Innovation Way, Suite 200

Newark, Delaware 19711

United States

Company Description

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. We provide quality services to pharmaceutical and biotechnology clients worldwide. Our linearly integrated co... more

Find other employees at this company (1,155)

Background Information

Employment History

Executive Director
BioReliance Corporation

Senior Scientist
Invitrogen Corporation

Post Doc and Staff Scientist
Salk Institute

Executive Director, Head of Genomics
Sigma-Aldrich Corporation

Senior Director, Research and Development
BioCoR Research


Master's degree
Molecular Biophysics and Biochemistry
Yale University

Master??s degree

Molecular Biophysics and Biochemistry
Yale University

undergraduate degree cum laude
Honors Biology and Chemistry
University of Illinois

Web References (26 Total References)

Press Releases | BioReliance

www.bioreliance.com [cached]

BioReliance Corporation announced today that John L. Kolman, PhD, has been named Senior Director, Research and Development.

John L. Kolman, ...

www.isbiotech.org [cached]

John L. Kolman, PhD

Independent Consultant

John L. Kolman, ...

www.isbiotech.org [cached]

John L. Kolman, PhD

Independent Consultant

BioReliance Heads to San Francisco for the World PGx Summit Next Week « SAFC Live – Blog on Biotech, Biopharma and Life Sciences SAFC Live – Blog on Biotech, Biopharma and Life Sciences

safclive.com [cached]

On Wednesday, May 1st at 9:50am, BioReliance's own John L. Kolman, Ph.D., Executive Director, Head of Genomics, will make a presentation titled: Validation of a Multiplex ADME SNP Assay for Clinical Trial Studies. The Illumina® VeraCode® ADME Core Panel - an alternative to DMET.

In this presentation, Dr. Kolman will address how assays for novel genetic biomarkers must be analytically validated to specific international regulations for use in late stage Clinical Trials. He will go on to provide a look into how skilled delivery of these services becomes more important as the industry embraces new FDA guidance on patient genotyping from CDER, CBER and CDRH (Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling). His presentation will then round out with a demonstration of the execution of an assay validation consistent with this guidance.
Click here to learn more about Dr. Kolman's presentation and what BioReliance has to offer.

Our own John Kolman, ...

safclive.com [cached]

Our own John Kolman, Executive Director and Head of Genomics for BioReliance will be featured speaking at 10:45am on Day Two about the "Validation of a multiplex ADME SNP assay for clinical trial studies: The Illumina® Vera Code® ADME core panel - an alternative to DMET".

Similar Profiles

Other People with this Name

Other people with the name Kolman

Michiel Kolman
Elsevier B.V

Ann Kolman
Endurance Re

Leonard Kolman
AF-Consult Switzerland Ltd

Beth Kolman
Cisco Systems Inc

Justin Kolman
Internap Network Services Corporation

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory